

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-11. (Cancelled)

12. (Previously Presented) A method of fertility control comprising administering to a subject in need thereof a synergistically effective amount of a nitric oxide synthase inhibitor in combination with an antiprogestin.

13. (Previously Presented) The method of claim 12, wherein the antiprogestin is mifepristone, ORG 31710, ORG 33 628, J867, CDB 2914, or ZK 137316.

14. (Previously Presented) The method of claim 12, wherein the treatment is performed postcoitally.

15-32. (Cancelled)

33. (Previously Presented) A method of fertility control for a woman, comprising administering to a woman in whom pregnancy is not desired and at risk for becoming pregnant a synergistically effective amount of a nitric oxide synthase inhibitor in combination with an antiprogestin.

34. (Previously Presented) The method of claim 33, wherein the antiprogestin is mifepristone, ORG 31710, ORG 33 628, J867, CDB 2914, or ZK 137316.

35. (Previously Presented) The method of claim 33, wherein the treatment is performed postcoitally.

36-47. (Cancelled)

48. (Previously Presented) The method of claim 33, wherein the nitric oxide synthase inhibitor is L-NAME.

49. (Previously Presented) The method of claim 12, wherein said antiprogesterin is administered in a dose ranging from 0.5 to 200 mg/day.

50. (Previously Presented) The method of claim 33, wherein said antiprogesterin is administered in a dose ranging from 0.5 to 200 mg/day.

51. (Previously Presented) A method of inhibiting the initiation of implantation of a conceptus comprising administering to a subject in need thereof a synergistically effective amount of a nitric oxide synthase inhibitor in combination with an antiprogesterin.

52. (Previously Presented) A method of inhibiting the maintenance of implantation of a conceptus comprising administering to a subject in need thereof a synergistically effective amount of a nitric oxide synthase inhibitor in combination with an antiprogesterin.

53. (Currently Amended) A method according to claim 12, wherein the antiprogesterin is

11 β -[4-N,N-(dimethylamino)phenyl]-17 α -hydroxy-17 β -(3-hydroxypropyl)-13 α -methyl-4,9(10)-gonadien-3-one,

11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(3-hydroxyprop-1(Z)-enyl)-4,9(10)-estradien-3-one, (EP-A 0 190 759),

~~11 β , 19-[4-(cyanophenyl)-o-phenylen]-17 β -hydroxy-17 α -(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one (WO-A 93/23020,~~

11 β , 19-[4-(cyanophenyl)-o-phenylen]-17 β -hydroxy-17 α -(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, or

11 β , 19-[4-(3-pyridinyl)-o-phenylen]-17 β -hydroxy-17 α -(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one (WO-A 93/23020).

54. (Previously Presented) A method according to claim 53, wherein the nitric oxide synthase inhibitor is L-NAME.